(Q37822915)

23 August 2017

1 reference

title

Future directions of stroke prevention in atrial fibrillation: the potential impact of novel anticoagulants and stroke risk stratification (English)

1 reference

23 August 2017

0 references

1 reference

1 reference

3

E M Hylek

1 reference

23 August 2017

K P Cabral

1

1 reference

PubMed ID

21176102

23 August 2017

J Ansell

series ordinal

2

1 reference

23 August 2017

1 March 2011

1 reference

Journal of Thrombosis and Haemostasis

23 August 2017

1 reference

23 August 2017

9

1 reference

23 August 2017

441-449

1 reference

23 August 2017

3

1 reference

Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence

23 August 2017

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2010.04179.X

Antithrombotic therapy in atrial fibrillation: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2010.04179.X

Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2010.04179.X

Stroke severity in atrial fibrillation. The Framingham Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2010.04179.X

Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2010.04179.X

Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2010.04179.X

Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2010.04179.X

Hospitalized patients with atrial fibrillation and a high risk of stroke are not being provided with adequate anticoagulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2010.04179.X

Underuse of oral anticoagulants in atrial fibrillation: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2010.04179.X

Challenges of establishing new antithrombotic therapies in atrial fibrillation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2010.04179.X

Comparison of outcomes among patients randomized to warfarin therapy according to anticoagulant control: results from SPORTIF III and V.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2010.04179.X

Benefit of oral anticoagulant over antiplatelet therapy in atrial fibrillation depends on the quality of international normalized ratio control achieved by centers and countries as measured by time in therapeutic range

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2010.04179.X

National surveillance of emergency department visits for outpatient adverse drug events

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2010.04179.X

Comparative pharmacodynamics and pharmacokinetics of oral direct thrombin and factor xa inhibitors in development

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2010.04179.X

Treatment of Proximal Deep-Vein Thrombosis With the Oral Direct Factor Xa Inhibitor Rivaroxaban (BAY 59-7939): The ODIXa-DVT (Oral Direct Factor Xa Inhibitor BAY 59-7939 in Patients With Acute Symptomatic Deep-Vein Thrombosis) Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2010.04179.X

Brave new world: the current and future use of novel anticoagulants

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2010.04179.X

New anticoagulants: anti IIa vs anti Xa--is one better?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2010.04179.X

Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2010.04179.X

Ximelagatran vs warfarin for stroke prevention in patients with nonvalvular atrial fibrillation: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2010.04179.X

Comparative efficacy and safety of the novel oral anticoagulants dabigatran, rivaroxaban and apixaban in preclinical and clinical development.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2010.04179.X

The metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2010.04179.X

Safety, pharmacodynamics, and pharmacokinetics of BAY 59-7939--an oral, direct Factor Xa inhibitor--after multiple dosing in healthy male subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2010.04179.X

The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2010.04179.X

Clinical pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor dabigatran etexilate

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2010.04179.X

Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2010.04179.X

Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2010.04179.X

Oral thrombin inhibitor dabigatran etexilate vs North American enoxaparin regimen for prevention of venous thromboembolism after knee arthroplasty surgery

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2010.04179.X

Dabigatran versus warfarin in the treatment of acute venous thromboembolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2010.04179.X

Dabigatran with or without concomitant aspirin compared with warfarin alone in patients with nonvalvular atrial fibrillation (PETRO Study).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2010.04179.X

Dabigatran versus warfarin in patients with atrial fibrillation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2010.04179.X

Rationale and design of RE-LY: randomized evaluation of long-term anticoagulant therapy, warfarin, compared with dabigatran

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2010.04179.X

Validation of Clinical Classification Schemes for Predicting Stroke

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2010.04179.X

Safety and tolerability of an immediate-release formulation of theoral direct thrombin inhibitor AZD0837 in the prevention of stroke and systemic embolism in patients with atrial fibrillation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2010.04179.X

Oral direct thrombin inhibitor AZD0837 for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation: a randomized dose-guiding, safety, and tolerability study of four doses of AZD0837 vs. vitamin K antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2010.04179.X

Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2010.04179.X

Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2010.04179.X

Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2010.04179.X

Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2010.04179.X

Rivaroxaban-once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation: rationale and design of the ROCKET AF study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2010.04179.X

Apixaban or enoxaparin for thromboprophylaxis after knee replacement

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2010.04179.X

Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2010.04179.X

Apixaban for reduction in stroke and other ThromboemboLic events in atrial fibrillation (ARISTOTLE) trial: design and rationale

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2010.04179.X

New oral anticoagulants in atrial fibrillation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2010.04179.X

Novel oral anticoagulants

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2010.04179.X

The first evaluation of a novel vitamin K antagonist, tecarfarin (ATI-5923), in patients with atrial fibrillation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2010.04179.X

Major hemorrhage and tolerability of warfarin in the first year of therapy among elderly patients with atrial fibrillation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2010.04179.X

Comparison of idraparinux with vitamin K antagonists for prevention of thromboembolism in patients with atrial fibrillation: a randomised, open-label, non-inferiority trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2010.04179.X

Risks and benefits of oral anticoagulation compared with clopidogrel plus aspirin in patients with atrial fibrillation according to stroke risk: the atrial fibrillation clopidogrel trial with irbesartan for prevention of vascular events (ACTIVE-W).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2010.04179.X

Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2010.04179.X

Interaction of cytochrome P450 3A inhibitors with P-glycoprotein

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2010.04179.X

Role of P-glycoprotein in pharmacokinetics: clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2010.04179.X

Drug and dietary interactions of the new and emerging oral anticoagulants

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2010.04179.X

Evaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: design and rationale for the Effective aNticoaGulation with factor xA next GEneration in Atrial Fibrillation-Thrombolysis In Myocardial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2010.04179.X

The role of P-glycoprotein and organic anion-transporting polypeptides in drug interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2010.04179.X

Drugs as P-glycoprotein substrates, inhibitors, and inducers

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2010.04179.X

10.1111/J.1538-7836.2010.04179.X

21 January 2018

Identifiers

DOI

1 reference

23 August 2017

1 reference

PubMed ID

21176102